ZA9806732B - Irreversible inhibitiors of tyrosine kinases - Google Patents

Irreversible inhibitiors of tyrosine kinases

Info

Publication number
ZA9806732B
ZA9806732B ZA9806732A ZA9806732A ZA9806732B ZA 9806732 B ZA9806732 B ZA 9806732B ZA 9806732 A ZA9806732 A ZA 9806732A ZA 9806732 A ZA9806732 A ZA 9806732A ZA 9806732 B ZA9806732 B ZA 9806732B
Authority
ZA
South Africa
Prior art keywords
inhibitiors
irreversible
tyrosine kinases
kinases
tyrosine
Prior art date
Application number
ZA9806732A
Inventor
Alexander James Bridges
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US5406097P priority Critical
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA9806732B publication Critical patent/ZA9806732B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/74Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
ZA9806732A 1997-07-29 1998-07-28 Irreversible inhibitiors of tyrosine kinases ZA9806732B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US5406097P true 1997-07-29 1997-07-29

Publications (1)

Publication Number Publication Date
ZA9806732B true ZA9806732B (en) 1999-02-02

Family

ID=21988521

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9806732A ZA9806732B (en) 1997-07-29 1998-07-28 Irreversible inhibitiors of tyrosine kinases

Country Status (4)

Country Link
US (2) US6127374A (en)
AU (1) AU8760798A (en)
WO (1) WO1999006378A1 (en)
ZA (1) ZA9806732B (en)

Families Citing this family (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) * 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
WO1999038845A1 (en) 1998-01-29 1999-08-05 Tularik Inc. Ppar-gamma modulators
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
EP1801112A1 (en) * 1998-05-26 2007-06-27 Warner-Lambert Company LLC Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
HU0102514A3 (en) * 1998-05-26 2002-03-28 Warner Lambert Co Pyrido-pyrimidin and pyrimido-pyrimidin derivatives as inhibitors of cellular proliferation and pharmaceutical compositions thereof
JP2002539072A (en) 1998-08-18 2002-11-19 ザ・レジェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア Prevention of airway mucus production by administration of Egf-r antagonist
CA2341374A1 (en) 1998-10-01 2000-04-13 Astrazeneca Ab Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases
DE19911510A1 (en) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
BR0009083B1 (en) 1999-03-17 2011-11-01 amide derivative comprising a core quinazolinone, process for the preparation of an amide derivative, pharmaceutical composition and use of an amide derivative.
NZ516633A (en) * 1999-06-21 2004-09-24 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
KR100709909B1 (en) * 1999-06-21 2007-04-24 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 Bicyclic heterocycles, medicaments containing these compounds and methods for the production thereof
SG148834A1 (en) * 1999-06-30 2009-01-29 Japan Tobacco Inc Compounds for the modulation of ppary activity
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
SK287401B6 (en) 1999-11-05 2010-09-07 Astrazeneca Ab Quinazoline derivatives, process for preparing the same and pharmaceutical composition containing the same and the use of them
US6384051B1 (en) * 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
MXPA02009855A (en) * 2000-04-08 2003-03-27 Boehringer Ingelheim Pharma Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them.
AU6118001A (en) 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
EE200200710A (en) * 2000-06-22 2004-06-15 Pfizer Products Inc. The substituted bicyclic derivatives for the treatment of abnormal cell growth
US6403580B1 (en) 2000-08-26 2002-06-11 Boehringer Ingelheim Pharma Kg Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE10042064A1 (en) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Chinazolines, medicaments containing these compounds, their use and processes for their preparation
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10063435A1 (en) * 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate medicaments containing these compounds, their use and processes for their preparation
CN1264824C (en) * 2001-02-21 2006-07-19 三菱制药株式会社 Quinazoline derivatives
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
WO2002092578A1 (en) * 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
BR0214499A (en) * 2001-12-12 2005-05-10 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth
EP1463506B1 (en) 2001-12-24 2009-10-21 Astrazeneca AB Substituted quinazoline derivatives as inhibitors of aurora kinases
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
DE10221018A1 (en) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Use of inhibitors of EGFR-mediated signal transduction in the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy
AT535254T (en) 2002-07-15 2011-12-15 Genentech Inc Treatment of cancer with anti-ErbB2 antibody rhuMAb 2c4
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
AU2003250701A1 (en) * 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
AU2003247141A1 (en) * 2002-08-01 2004-02-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2499816C (en) 2002-09-27 2013-07-30 Xencor, Inc. Optimized fc variants and methods for their generation
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
AT380810T (en) * 2002-10-09 2007-12-15 Critical Outcome Technologies Protein-tyrosine kinase inhibitors
DK1847539T3 (en) 2002-12-24 2009-11-09 Astrazeneca Ab Quinazoline derivatives
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
WO2004106308A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CA2531327A1 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. Compounds and therapeutical use thereof
CN103664802B (en) 2003-08-14 2015-08-05 阿雷生物药品公司 As receptor tyrosine kinase inhibitors quinazoline analogs
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US7569577B2 (en) 2003-09-16 2009-08-04 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
DK2210607T3 (en) 2003-09-26 2011-12-12 Exelixis Inc N- [3-fluoro-4 - ({6- (methyloxy) -7 - [(3-morpholin-4-ylpropyl) oxy] quinolin-4-yl} oxy) phenyl] -N '- (4-fluorophenyl) cyclopropane-1,1-dicarboxamide for the treatment of cancer
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
DE10349113A1 (en) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma A process for preparing Aminocrotonylverbindungen
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
CN103394083B (en) 2003-11-06 2017-07-18 西雅图基因公司 It can be coupled with a ligand compound monomethyl valine
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
US20050171172A1 (en) * 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as PDGFR modulators
CN1914182B (en) 2004-02-03 2011-09-07 阿斯利康(瑞典)有限公司 Quinazoline derivatives
CA2561516A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
SI1733056T1 (en) 2004-03-31 2013-10-30 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
SI1746999T1 (en) 2004-05-06 2012-01-31 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
CN1972934A (en) 2004-06-28 2007-05-30 奥坦纳医药公司 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
SI2471813T1 (en) 2004-07-15 2015-03-31 Xencor, Inc. Optimized Fc variants
JPWO2006025490A1 (en) * 2004-09-01 2008-05-08 田辺三菱製薬株式会社 Molecular chaperone function regulating agent
EP1791565B1 (en) 2004-09-23 2016-04-20 Genentech, Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
KR101027427B1 (en) 2004-11-12 2011-04-11 젠코어 인코포레이티드 Fc VARIANTS WITH INCREASED BINDING TO FcRn
EP1838712B8 (en) 2004-12-14 2011-10-12 AstraZeneca AB Pyrazolopyrimidine compounds as antitumor agents
WO2006071079A1 (en) * 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
GB0428475D0 (en) * 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc Compounds and therapeutical use thereof
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
WO2006085330A2 (en) * 2005-02-14 2006-08-17 Hadasit Medical Research Services And Development Ltd. Use of protein tyrosine kinase inhibitors for the treatment of leiomyomas
MX2007009889A (en) 2005-02-23 2007-09-07 Genentech Inc Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor.
CA2612788A1 (en) * 2005-06-24 2006-12-28 Steven Cesar Alfons De Jonghe Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c
WO2007029251A2 (en) * 2005-09-06 2007-03-15 T.K. Signal Ltd. Polyalkylene glycol derivatives of 4- (phenylamino)quinazolines useful as irreversible inhibitors of epidermal gr0wth fact0r receptor tyrosine kinase
ES2354457T3 (en) 2005-09-20 2011-03-15 Astrazeneca Ab Compounds of 4- (1H-indazol-5-ylamino) quinazoline as inhibitors of erbB receptor tyrosine kinase for treating cancer.
CA2833706C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
AT507224T (en) 2005-11-15 2011-05-15 Array Biopharma Inc Methods and intermediates for the preparation of N4-phenyl-quinazoline-4-amine derivatives
CN101003514A (en) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 Derivative of quinazoline, preparation method and usage
US8338435B2 (en) * 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
US8246966B2 (en) * 2006-08-07 2012-08-21 University Of Georgia Research Foundation, Inc. Trypanosome microsome system and uses thereof
ES2402591T3 (en) 2006-08-14 2013-05-07 Xencor Inc. Optimized antibodies that select as target CD19
EP2386655B1 (en) 2006-09-12 2014-11-19 Genentech, Inc. Methods and compositions for the diagnosis and treatment of lung cancer using KIT or KDG gene as genetic marker
MX2009002710A (en) 2006-09-18 2009-03-25 Boehringer Ingelheim Int Method for treating cancer harboring egfr mutations.
WO2008066755A2 (en) 2006-11-22 2008-06-05 University Of Georgia Research Foundation, Inc. Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
TW200840584A (en) * 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
WO2008083491A1 (en) 2007-01-11 2008-07-17 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
TWI352199B (en) 2007-03-02 2011-11-11 Genentech Inc Predicting response to a her inhibitor
CA2693053A1 (en) 2007-05-30 2008-12-11 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
ES2417148T3 (en) 2007-06-08 2013-08-06 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
ES2392639T3 (en) 2008-02-07 2012-12-12 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles, medicaments containing these compounds, their use and process for their preparation
CN101544609A (en) 2008-03-25 2009-09-30 上海艾力斯医药科技有限公司 Crystallization form of 4-anilinoquinazoline derivatives
KR20110014192A (en) 2008-05-13 2011-02-10 아스트라제네카 아베 Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-([1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy)quinazoline
EP2288727B1 (en) 2008-05-14 2013-07-10 Genomic Health, Inc. Predictors of patient response to treatment with egf receptor inhibitors
US8426430B2 (en) * 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
WO2011011027A1 (en) 2009-07-20 2011-01-27 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
EP2241565A1 (en) 2009-01-15 2010-10-20 Universität Leipzig Aurora kinase inhibitors compounds
EP2387563B1 (en) 2009-01-16 2013-03-06 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
AU2010221818A1 (en) 2009-03-11 2011-10-06 Auckland Uniservices Limited Prodrug forms of kinase inhibitors and their use in therapy
EP2451445B1 (en) 2009-07-06 2019-04-03 Boehringer Ingelheim International GmbH Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
NZ598144A (en) 2009-09-02 2014-01-31 Auckland Uniservices Ltd Kinase inhibitors, prodrug forms thereof and their use in therapy
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
AU2010310746B2 (en) 2009-10-20 2015-07-23 Nestec S.A. Proximity-mediated assays for detecting oncogenic fusion proteins
BR112012017269A2 (en) 2010-01-12 2016-05-03 Hoffmann La Roche tricyclic heterocyclic compounds, compositions and methods of use thereof
CA2800230A1 (en) 2010-03-04 2011-09-09 Hospital District Of Southwest Finland Method for selecting patients for treatment with an egfr inhibitor
MX2012010265A (en) 2010-03-17 2012-10-01 Hoffmann La Roche Imidazopyridine and purine compounds, compositions and methods of use.
JP2013523098A (en) 2010-03-29 2013-06-17 ザイムワークス,インコーポレイテッド Antibody with enhanced or suppressed effector function
EP3235818A3 (en) 2010-04-01 2018-03-14 Critical Outcome Technologies, Inc. Compounds for the treatment of hiv
EP2558864A1 (en) 2010-04-16 2013-02-20 Genentech, Inc. Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
CN102382106A (en) 2010-08-30 2012-03-21 黄振华 Aniline substituted quinazoline derivative
MX2013003019A (en) 2010-09-15 2013-05-28 Hoffmann La Roche Azabenzothiazole compounds, compositions and methods of use.
EP2637692A4 (en) 2010-11-12 2014-09-10 Scott & White Healthcare Antibodies to tumor endothelial marker 8
EP2640722B1 (en) 2010-11-19 2015-11-04 F.Hoffmann-La Roche Ag Pyrazolopyridines and their use as tyk2 inhibitors
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
BR112013020992A2 (en) 2011-02-17 2016-10-11 Nestec Sa apparatus and method for the isolation of leukocytes and tumor cells by filtration
JP5832559B2 (en) 2011-03-10 2015-12-16 オメロス コーポレーション Generation of anti-FN14 monoclonal antibodies by accelerated antibody evolution ex vivo
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
WO2013013640A1 (en) * 2011-07-27 2013-01-31 上海医药集团股份有限公司 Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof
US9102724B2 (en) 2011-08-12 2015-08-11 Omeros Corporation Anti-FZD10 monoclonal antibodies and methods for their use
ES2573336T3 (en) 2011-08-12 2016-06-07 F. Hoffmann-La Roche Ag Indazole compounds, compositions and methods of use
RU2014113236A (en) 2011-09-20 2015-10-27 Ф. Хоффманн-Ля Рош Аг Imidazopyridine compounds, compositions and methods of application
WO2013134743A1 (en) 2012-03-08 2013-09-12 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
DK2844282T3 (en) 2012-05-04 2019-07-15 Pfizer Prostata associated antigenes and vaccine-based immunterapiregimenes
US9550738B2 (en) * 2012-05-14 2017-01-24 Hangzhouderenyucheng Biotechnology Ltd Bicyclic compounds as kinases inhibitors
KR20150130491A (en) 2013-03-13 2015-11-23 제넨테크, 인크. Pyrazolo compounds and uses thereof
CN107501110A (en) 2013-03-14 2017-12-22 阿尔克梅斯制药爱尔兰有限公司 Prodrugs of fumarates and their use in treating various diseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
TWI623551B (en) 2013-08-02 2018-05-11 輝瑞大藥廠 Anti-cxcr4 antibodies and antibody-drug conjugates
JP6336598B2 (en) 2013-09-05 2018-06-06 ジェネンテック, インコーポレイテッド Antiproliferative compound
KR20160055253A (en) 2013-09-12 2016-05-17 할로자임, 아이엔씨 Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2015036792A1 (en) 2013-09-16 2015-03-19 Astrazeneca Ab Therapeutic polymeric nanoparticles and methods of making and using same
WO2015049325A1 (en) 2013-10-03 2015-04-09 F. Hoffmann-La Roche Ag Therapeutic inhibitors of cdk8 and uses thereof
CN105828837A (en) 2013-12-17 2016-08-03 豪夫迈·罗氏有限公司 Methods of treating cancers using pd-1 axis binding antagonists and taxanes
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CA2940845A1 (en) 2014-02-24 2015-08-27 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
JP2017514795A (en) 2014-03-31 2017-06-08 ジェネンテック, インコーポレイテッド Combination therapy comprising an anti-angiogenic agent and an OX40 binding agonist
EP3126394A1 (en) 2014-03-31 2017-02-08 F.Hoffmann-La Roche Ag Anti-ox40 antibodies and methods of use
CN107074823A (en) 2014-09-05 2017-08-18 基因泰克公司 Therapeutic compounds and uses thereof
WO2016044694A1 (en) 2014-09-19 2016-03-24 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer
JP2017530984A (en) 2014-10-10 2017-10-19 ジェネンテック, インコーポレイテッド Pyrrolidone amide compounds as inhibitors of histone demethylase
EP3209797B1 (en) 2014-10-20 2018-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for screening a subject for a cancer
RU2017119009A3 (en) 2014-11-03 2019-06-14
US20160152720A1 (en) 2014-11-06 2016-06-02 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
JP2017533249A (en) 2014-11-10 2017-11-09 ジェネンテック, インコーポレイテッド Substituted pyrrolopyridines as inhibitors of bromodomains
JP2017533248A (en) 2014-11-10 2017-11-09 ジェネンテック, インコーポレイテッド Substituted pyrrolopyridines as inhibitors of bromodomains
EP3218376A1 (en) 2014-11-10 2017-09-20 Genentech, Inc. Bromodomain inhibitors and uses thereof
SG11201703605QA (en) 2014-11-17 2017-06-29 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
JP2017537100A (en) 2014-11-27 2017-12-14 ジェネンテック, インコーポレイテッド 4,5,6,7-Tetrahydro-1H-pyrazolo [4,3-C] pyridin-3-amine compounds as CBP and / or EP300 inhibitors
EP3229836A1 (en) 2014-12-09 2017-10-18 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
KR20170094165A (en) 2014-12-23 2017-08-17 제넨테크, 인크. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
CN107208138A (en) 2014-12-30 2017-09-26 豪夫迈·罗氏有限公司 Methods and compositions for prognosis and treatment of cancers
EP3242875A1 (en) 2015-01-09 2017-11-15 Genentech, Inc. 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
CN107406429A (en) 2015-01-09 2017-11-28 基因泰克公司 Pyridazinone derivatives and their use in the treatment of cancer
EP3242872B1 (en) 2015-01-09 2019-07-03 Genentech, Inc. (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
WO2016123391A1 (en) 2015-01-29 2016-08-04 Genentech, Inc. Therapeutic compounds and uses thereof
WO2016123387A1 (en) 2015-01-30 2016-08-04 Genentech, Inc. Therapeutic compounds and uses thereof
JP2018510851A (en) 2015-02-25 2018-04-19 ジェネンテック, インコーポレイテッド Therapeutic pyridazine compounds and uses thereof
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
JP2018516537A (en) 2015-04-07 2018-06-28 ジェネンテック, インコーポレイテッド Antigen binding complex having agonistic activity and method of use thereof
EP3303632A1 (en) 2015-05-29 2018-04-11 H. Hoffnabb-La Roche Ag Therapeutic and diagnostic methods for cancer
EP3303397A1 (en) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
WO2016200836A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies
JP2018522851A (en) 2015-06-17 2018-08-16 ジェネンテック, インコーポレイテッド Method for treating locally advanced or metastatic breast cancer using PD-1 axis binding antagonist and taxane
WO2017005847A1 (en) 2015-07-07 2017-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to myosin 18a and uses thereof
WO2017033019A1 (en) 2015-08-26 2017-03-02 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii (Cnio) Condensed tricyclic compounds as protein kinase inhibitors
WO2017032867A1 (en) 2015-08-27 2017-03-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a lung cancer
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
MX2018010295A (en) 2016-02-26 2019-06-06 Inst Nat Sante Rech Med Antibodies having specificity for btla and uses thereof.
CA3015528A1 (en) 2016-02-29 2017-09-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
CN109154613A (en) 2016-04-15 2019-01-04 豪夫迈·罗氏有限公司 For monitoring and the method for the treatment of cancer
KR20190003957A (en) 2016-04-15 2019-01-10 제넨테크, 인크. Cancer monitoring and treatment methods
AU2017249229A1 (en) 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
EP3464270A2 (en) 2016-05-24 2019-04-10 Genentech, Inc. Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
EP3464286A1 (en) 2016-05-24 2019-04-10 Genentech, Inc. Pyrazolopyridine derivatives for the treatment of cancer
JP2019516754A (en) 2016-05-25 2019-06-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods and compositions for treating cancer
EP3469099A1 (en) 2016-06-08 2019-04-17 H. Hoffnabb-La Roche Ag Diagnostic and therapeutic methods for cancer
US20170355766A1 (en) 2016-06-08 2017-12-14 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells in igg4-related diseases
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
EP3491022A1 (en) 2016-07-29 2019-06-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Antibodies targeting tumor associated macrophages and uses thereof
US20180057598A1 (en) 2016-08-05 2018-03-01 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
CN109476748A (en) 2016-08-08 2019-03-15 豪夫迈·罗氏有限公司 Treatment and diagnostic method for cancer
WO2018068028A1 (en) 2016-10-06 2018-04-12 Genentech, Inc. Therapeutic and diagnostic methods for cancer
CA3039348A1 (en) 2016-10-21 2018-04-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for promoting t cells response
WO2018081648A2 (en) 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use
WO2018087391A1 (en) 2016-11-14 2018-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
TW201837467A (en) 2017-03-01 2018-10-16 美商建南德克公司 Diagnostic and therapeutic methods for cancer
WO2018158398A1 (en) 2017-03-02 2018-09-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
AU2018250875A1 (en) 2017-04-13 2019-10-03 F. Hoffmann-La Roche Ag An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
WO2018189403A1 (en) 2017-04-14 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
WO2018211007A1 (en) 2017-05-18 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of mast cell diseases
TW201908730A (en) 2017-07-21 2019-03-01 美商建南德克公司 The diagnosis and treatment of cancer
WO2019033043A2 (en) 2017-08-11 2019-02-14 Genentech, Inc. Anti-cd8 antibodies and uses thereof
TW201919707A (en) 2017-09-08 2019-06-01 美商建南德克公司 Diagnostic and therapeutic methods for cancer
WO2019072885A1 (en) 2017-10-11 2019-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Magnetic nanoparticles for the treatment of cancer
WO2019072888A1 (en) 2017-10-11 2019-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting hepatocellular carcinoma treatment response
WO2019090263A1 (en) 2017-11-06 2019-05-09 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2019101956A1 (en) 2017-11-24 2019-05-31 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for treating cancers
WO2019110750A1 (en) 2017-12-07 2019-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for screening a subject for a cancer
WO2019148043A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2019148036A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2019148044A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2019165434A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
PT100905A (en) * 1991-09-30 1994-02-28 Eisai Co Ltd Bicycle hygieneous heterocyclic compounds containing benzene, cyclohexan or pyridine and pyrimidine, pyridine or imidazole substitutes and pharmaceutical compositions containing them
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248D0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
HUT76291A (en) * 1994-02-23 1997-07-28 Pfizer 4-heterocyclyl-substituted quinazoline derivatives and pharmaceutical compositions containing them
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (en) * 1994-11-12 1997-12-01 Zeneca Ltd
WO1997038983A1 (en) * 1996-04-12 1997-10-23 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases

Also Published As

Publication number Publication date
AU8760798A (en) 1999-02-22
US6127374A (en) 2000-10-03
WO1999006378A1 (en) 1999-02-11
US6562818B1 (en) 2003-05-13

Similar Documents

Publication Publication Date Title
EG24028A (en) Aminothiazole inhibitors of cyclin dependent kinases
PL201336B1 (en) 2-phenyl-substituted imidazotriazinones as inhibitors of phosphodiesterase
EP1019100A4 (en) Controlled release of substances
EP1018987A4 (en) Neocartilage and methods of use
ZA9800376B (en) Sulfamide-metalloprotease inhibitors
IL141434D0 (en) Quinazoline derivatives
GR20010300007T1 (en) Inhibition of raf kinase using substituted heterocyclic ureas
GB9603095D0 (en) Quinazoline derivatives
GB9607729D0 (en) Quinazoline derivatives
AU1371999A (en) Benzothiazole protein tyrosine kinase inhibitors
HU9700344D0 (en) Substituted quinazoline derivatives
HK1054931A1 (en) Tyrosine kinase inhibitors
EP1218376A4 (en) Tyrosine kinase inhibitors
EP1161433A4 (en) Tyrosine kinase inhibitors
EP1226119A4 (en) Tyrosine kinase inhibitors
PL184715B1 (en) Inhibitors of proteinous kinase c
PL204437B1 (en) Pyrrolotriazine inhibitors of kinases
AP200001786A0 (en) Therapeutic uses of quinoline derivatives
IL141724D0 (en) INHIBITORS OF P38-α KINASE
PT1015585E (en) Homes of tie ligandos
EP0794789A4 (en) Inhibitors of prenyl transferases
PL337442A1 (en) Expression adjustment of quinolane phosphoribozyltransferase
PL352714A1 (en) Diaminothiazoles and their use for inhibiting protein kinases
GR3036433T3 (en) Treatment of gaseous emissions
GB9227026D0 (en) Dual inhibitors of no synthase and cycloosygenase